Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 92,803,223 shares, an increase of 36.6% from the October 31st total of 67,929,666 shares. Based on an average trading volume of 37,712,746 shares, the days-to-cover ratio is presently 2.5 days.

Large investors have recently made changes to their positions in the business. Exane Derivatives acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth about $571,000. Korea Investment CORP increased its stake in Teva Pharmaceutical Industries by 14.3% during the third quarter. Korea Investment CORP now owns 244,774 shares of the company’s stock worth $4,308,000 after acquiring an additional 30,674 shares during the last quarter. Financial Counselors Inc. increased its stake in Teva Pharmaceutical Industries by 5.7% during the second quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock worth $4,671,000 after acquiring an additional 7,571 shares during the last quarter. Private Capital Management Inc. increased its stake in Teva Pharmaceutical Industries by 51.3% during the third quarter. Private Capital Management Inc. now owns 26,100 shares of the company’s stock worth $459,000 after acquiring an additional 8,850 shares during the last quarter. Finally, Lockheed Martin Investment Management Co. acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth about $317,000. Institutional investors own 52.05% of the company’s stock.

Shares of Teva Pharmaceutical Industries (TEVA) opened at $15.26 on Friday. The company has a market capitalization of $15,057.12, a PE ratio of 3.42 and a beta of 0.55. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $38.31.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.085 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $0.34 annualized dividend and a yield of 2.23%. Teva Pharmaceutical Industries’s dividend payout ratio is presently -16.97%.

A number of research firms have recently weighed in on TEVA. Barclays cut their price target on Teva Pharmaceutical Industries from $38.00 to $23.00 and set an “equal weight” rating for the company in a report on Monday, August 7th. BidaskClub raised Teva Pharmaceutical Industries from a “strong sell” rating to a “sell” rating in a report on Wednesday, September 13th. Gabelli reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, September 13th. UBS reissued a “neutral” rating and issued a $19.00 price target on shares of Teva Pharmaceutical Industries in a report on Thursday, September 14th. Finally, Maxim Group reiterated a “hold” rating and issued a $15.50 target price on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 14th. Seven research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $21.65.

TRADEMARK VIOLATION WARNING: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-short-interest-up-36-6-in-november/1740695.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.